Swiss National Bank Sells 31,000 Shares of Henry Schein, Inc. $HSIC

Swiss National Bank decreased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 12.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 210,600 shares of the company’s stock after selling 31,000 shares during the quarter. Swiss National Bank owned about 0.17% of Henry Schein worth $15,384,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in HSIC. Choreo LLC acquired a new stake in shares of Henry Schein in the 1st quarter valued at about $224,000. Cetera Investment Advisers boosted its holdings in shares of Henry Schein by 14.7% in the 1st quarter. Cetera Investment Advisers now owns 4,924 shares of the company’s stock worth $337,000 after buying an additional 630 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Henry Schein by 24,700.0% in the 1st quarter. Assetmark Inc. now owns 6,200 shares of the company’s stock worth $425,000 after purchasing an additional 6,175 shares during the period. HB Wealth Management LLC lifted its position in shares of Henry Schein by 1.5% during the 1st quarter. HB Wealth Management LLC now owns 15,419 shares of the company’s stock valued at $1,056,000 after buying an additional 226 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in Henry Schein by 766.5% during the first quarter. Federated Hermes Inc. now owns 2,045 shares of the company’s stock worth $140,000 after purchasing an additional 1,809 shares during the period. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $75.25 on Thursday. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The firm’s 50 day moving average price is $67.47 and its 200-day moving average price is $69.34. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $8.86 billion, a PE ratio of 24.27, a price-to-earnings-growth ratio of 2.06 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.27 by $0.11. The firm had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Equities research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HSIC shares. Evercore ISI upped their price target on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Morgan Stanley upped their price target on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a report on Wednesday, November 5th. Wells Fargo & Company raised their price target on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. upped their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Henry Schein currently has an average rating of “Hold” and a consensus price target of $76.08.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.